Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2003 3
2004 1
2007 1
2008 5
2009 7
2010 7
2011 6
2012 11
2013 24
2014 26
2015 19
2016 14
2017 14
2018 13
2019 13
2020 8
2021 11
2022 12
2023 9
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 24699939

159 results

Results by year

Filters applied: . Clear all
Page 1
Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial.
Huizinga TW, Fleischmann RM, Jasson M, Radin AR, van Adelsberg J, Fiore S, Huang X, Yancopoulos GD, Stahl N, Genovese MC. Huizinga TW, et al. Ann Rheum Dis. 2014 Sep;73(9):1626-34. doi: 10.1136/annrheumdis-2013-204405. Epub 2013 Dec 2. Ann Rheum Dis. 2014. PMID: 24297381 Free PMC article. Clinical Trial.
Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study.
Takeuchi T, Thorne C, Karpouzas G, Sheng S, Xu W, Rao R, Fei K, Hsu B, Tak PP. Takeuchi T, et al. Ann Rheum Dis. 2017 Dec;76(12):2001-2008. doi: 10.1136/annrheumdis-2017-211328. Epub 2017 Aug 30. Ann Rheum Dis. 2017. PMID: 28855173 Free PMC article. Clinical Trial.
Efficacy and safety of sirukumab in Japanese patients with active rheumatoid arthritis who were refractory or intolerant to anti-tumor necrosis factor therapy: Subgroup analysis of a randomized, double-blind, multicenter, phase 3 study (SIRROUND-T).
Tanaka Y, Takeuchi T, Harigai M, Yamanaka H, Nakano T, Akagi K, Ukyo Y, Hsu B. Tanaka Y, et al. Mod Rheumatol. 2019 Mar;29(2):306-313. doi: 10.1080/14397595.2018.1452345. Epub 2018 Apr 13. Mod Rheumatol. 2019. PMID: 29532734 Clinical Trial.
Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study.
Taylor PC, Schiff MH, Wang Q, Jiang Y, Zhuang Y, Kurrasch R, Daga S, Rao R, Tak PP, Hsu B. Taylor PC, et al. Ann Rheum Dis. 2018 May;77(5):658-666. doi: 10.1136/annrheumdis-2017-212496. Epub 2018 Feb 26. Ann Rheum Dis. 2018. PMID: 29483080 Clinical Trial.
Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial.
Taylor PC, Quattrocchi E, Mallett S, Kurrasch R, Petersen J, Chang DJ. Taylor PC, et al. Ann Rheum Dis. 2011 Dec;70(12):2119-25. doi: 10.1136/ard.2011.151522. Epub 2011 Aug 22. Ann Rheum Dis. 2011. PMID: 21859685 Free PMC article. Clinical Trial.
Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study.
Feist E, Fatenejad S, Grishin S, Korneva E, Luggen ME, Nasonov E, Samsonov M, Smolen JS, Fleischmann RM. Feist E, et al. Ann Rheum Dis. 2022 Dec;81(12):1661-1668. doi: 10.1136/ard-2022-222630. Epub 2022 Sep 15. Ann Rheum Dis. 2022. PMID: 36109142 Free PMC article. Clinical Trial.
159 results